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Clara E. Pavillet, Álvaro Lopez Malizia, Juan Sabatté, Jorge Raul Geffner  
and Ana Ceballos
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Inflammatory dendritic cells (DCs) are a distinct subset of DCs that derive from circulating 
monocytes infiltrating injured tissues. Monocytes can differentiate into DCs with different 
functional signatures, depending on the presence of environment stimuli. Among these 
stimuli, transforming growth factor-beta (TGF-β) and prostaglandin E2 (PGE2) have been 
shown to modulate the differentiation of monocytes into DCs with different phenotypes 
and functional profiles. In fact, both mediators lead to contrasting outcomes regarding 
the production of inflammatory and anti-inflammatory cytokines. Previously, we have 
shown that human semen, which contains high concentrations of PGE2, promoted 
the differentiation of DCs into a tolerogenic profile through a mechanism dependent on 
signaling by E-prostanoid receptors 2 and 4. Notably, this effect was induced despite 
the huge concentration of TGF-β present in semen, suggesting that PGE2 overrides the 
influence exerted by TGF-β. No previous studies have analyzed the joint actions induced 
by PGE2 and TGF-β on the function of monocytes or DCs. Here, we analyzed the pheno-
type and functional profile of monocyte-derived DCs differentiated in the presence of 
TGF-β and PGE2. DC differentiation guided by TGF-β alone enhanced the expression of 
CD1a and abrogated LPS-induced expression of IL-10, while differentiation in the pres-
ence of PGE2 impaired CD1a expression, preserved CD14 expression, abrogated IL-12 
and IL-23 production, stimulated IL-10 production, and promoted the expansion of 
FoxP3+ regulatory T cells in a mixed lymphocyte reaction. Interestingly, DCs differentiated 
in the presence of TGF-β and PGE2 showed a phenotype and functional profile closely 
resembling those induced by PGE2 alone. Finally, we found that PGE2 inhibited TGF-β 
signaling through an action exerted by EP2 and EP4 receptors coupled to cyclic AMP 
increase and protein kinase A activity. These results indicate that PGE2 suppresses the 
influence exerted by TGF-β during DC differentiation, imprinting a tolerogenic signature. 
High concentrations of TGF-β and PGE2 are usually found in infectious, autoimmune, 
and neoplastic diseases. Our observations suggest that in these scenarios PGE2 might 
play a mandatory role in the acquisition of a regulatory profile by DCs.
Keywords: prostaglandin e2, monocytes, dendritic cells, TgF-β, inflammation, il-10
Abbreviations: cAMP, cyclic adenosine mono-phosphate; CFSE, carboxyfluorescein succinimidyl ester; COX2, prostaglandin-
endoperoxide synthase-2; CREB, cAMP-responsive-element binding protein; DC, dendritic cell; MDSC, myeloid-derived 
suppressor cell; PGE2, prostaglandin E2; PKA, protein kinase A; PI3K, phosphatidylinositol-3-phosphate kinase; TGF-β, 
transforming growth factor-beta.
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inTrODUcTiOn
Dendritic cells (DCs) comprise a heterogeneous group of cells 
characterized by their ability not only to induce T cell activation 
but also to silence T cell immune responses. So called “inflamma-
tory” DCs are a distinct subset of DCs derived from monocytes 
that infiltrate pathogen-induced or sterile inflammation sites (1). 
Inflammatory DCs show high plasticity, which enables them to 
induce the differentiation of CD4+ T cells into different effector 
profiles (2–5). They can also differentiate into tolerogenic DCs to 
keep the immune response under control (6). Microenvironmental 
signals sensed by infiltrating monocytes during their differentia-
tion determine the functional profile of DCs (7), although it is still 
unclear how the acquisition of a particular signature is regulated 
in vivo.
Transforming growth factor-β (TGF-β) is found at increased 
levels at inflammatory sites, either during acute or chronic stages 
of inflammation, as well as in tumor microenvironments. TGF-β 
is usually associated with the resolution of inflammatory process 
by dampening the activation of T lymphocytes through different 
mechanisms (8). For instance, TGF-β is known to suppress the 
function of effector CD4+ and CD8+ T  cells, to promote the 
activation of naïve CD4+ T  cells into a regulatory profile and 
to suppress the activation of natural killer cells (9–11). The 
pleiotropic nature of TGF-β action is evident when analyzing 
its effect on myeloid cells. Loss of TGF-β signaling specifically 
in conventional DCs promotes autoimmune encephalomyelitis 
and spontaneous multiorgan autoimmunity (12, 13), without 
affecting DC maturation and IL-12 secretion in the scenario of 
Leishmania infection (13, 14). In the early periods of inflam-
mation, TGF-β appears to act as a pro-inflammatory agent by 
recruiting and activating resting monocytes, notably increasing 
their susceptibility to be activated through the receptor for the Fc 
portion of IgG type III (CD16) (15, 16). Furthermore, monocytes 
cultured with TGF-β (together with GM-CSF and IL-4), differ-
entiate toward Langerhans cell (LC)-like DCs that are unable to 
produce IL-10 but have a great capacity to secrete IL-12 upon 
stimulation (17, 18).
Prostaglandin E2 (PGE2), a pleotropic molecule derived 
from arachidonic acid metabolism, is another ubiquitous immu-
nomodulator known to influence differentiation of DCs. Its 
concentration rapidly increases in acute inflammatory processes 
(19, 20), promoting local vasodilation, increasing microvascular 
permeability, and favoring the extravasation of blood granulo-
cytes and the activation of mast cells (21). Paradoxically, PGE2 
is also known for a wide range of immunosuppressive functions 
like inhibition of neutrophil and NK  cell activation, inhibition 
of T cell proliferation, and abolishing secretion of inflammatory 
factors like TNF-α and IL-12 from monocytes, macrophages, 
and DCs (22–24). In the course of DC differentiation induced 
by GM-CSF and IL-4, PGE2 has been shown to promote the 
development of myeloid-derived suppressor cells (MDSCs) (25). 
Interestingly, contrasting with the actions mediated by TGF-β, 
PGE2 has been shown to enhance IL-10 expression and abrogate 
IL-12 production by DCs (21).
Because high concentrations of TGF-β and PGE2 are found in 
the course of infectious, autoimmune, and neoplastic diseases, 
previous studies have focused on the biological actions induced 
by the presence of both mediators. It has been reported that 
PGE2 antagonizes TGF-β signaling in a variety of cell types, 
including liver stellate cells, mammary epithelial cells, and lung 
fibroblasts (26–28). For instance, PGE2 is a known anti-fibrotic 
modulator which counteracts TGF-β pro-fibrotic effects in the 
liver by acting on stellate cells and fibroblasts (29). Moreover, 
PGE2 has been shown to inhibit TGF-β-induced mesenchymal 
epithelial transition (30, 31). On the other hand, it has also 
been reported that PGE2 can act synergically with TGF-β. In 
this regard, TGF-β has shown to synergize with PGE2 in the 
induction of FoxP3 expression in CD4+ T  lymphocytes as 
well as in the inhibition of IFN-α secretion by plasmacytoid 
DCs (32–34). In a previous study, we found that semen, which 
contains very high levels of TGF-β and PGE2 (35, 36), guided 
the differentiation of monocytes into tolerogenic DCs through 
a mechanism dependent on signaling by E-prostanoid receptors 
2 and 4 (37). However, there are no previous studies specifically 
aimed at analyzing the effect of TGF-β and PGE2 acting together 
on monocytes or DCs.
In this work, we found that the presence of PGE2 at the 
onset of the differentiation of monocytes into DCs antagonizes 
phenotypic and functional signatures induced by TGF-β. We 
observed that PGE2, in a concentration-dependent manner, 
skewed the CD1a+ CD14− phenotype stimulated by TGF-β 
toward a CD1a− CD14+ phenotype. More importantly, we 
found that the presence of PGE2, in concentrations as low as 
10−7 M, defined the functional properties of DCs, antagonizing 
the influence of TGF-β. In fact, PGE2 reversed TGF-β-mediated 
inhibition of IL-10 and abrogated IL-12 and IL-23 production, 
leading to expansion of FoxP3+ regulatory T cells in a mixed 
lymphocyte reaction. We also found that PGE2 interfered with 
TGF-β signaling by increasing cyclic adenosine mono-phos-
phate (cAMP), without affecting Smad2 and Smad3 entry into 
the nucleus, in agreement with a mechanism that was previ-
ously described in fibroblasts (38). Our results contribute to the 
understanding of monocyte fate in inflammatory and tumoral 
contexts, and suggest that the presence of PGE2 could mask 
the pro-inflammatory actions exerted by TGF-β on monocytes, 
favoring the acquisition of a tolerogenic signature by monocyte-
derived DCs.
MaTerials anD MeThODs
reagents
LPS from Escherichia coli O111:B4, PHA from Phaseolus 
vulgaris, H-89 [protein kinase A (PKA) inhibitor], forskolin 
(adenylate cyclase activator), and PGE2 were obtained from 
Sigma-Aldrich. AS-605240 [phosphatidylinositol-3-phos-
phate kinase (PI3K) inhibitor], PF-04418948 (EP2 receptor 
antagonist), and L-161,962 (EP4 receptor antagonist) were 
purchased from Cayman Chemical. Ficoll-Hypaque was 
obtained from GE Healthcare. Recombinant human TGF-β1, 
recombinant human M-CSF, recombinant human IL-4, and 
recombinant human GM-CSF were obtained from Miltenyi 
Biotech.
Table 1 | List of antibodies used for flow cytometry.
brand clone Fluorochrome catalog
CD1a BD HI149 APC 559775
CD1a BD HI149 FITC 555397
CD14 BD M5E2 BV421 563743
CD14 BD M5E2 FITC 555397
CD1c BD F10/21A3 PE 564900
CD11b BD ICRF44 PE 555388
HLA-DR BD L243 APC 340691
CD206 BD 19.2 PE 555954
DC-SIGN BD DCN46 APC 551545
CD16 BioLegend 3G8 APC 561248
CD80 BD L307.4 FITC 557226
CD83 BD HB15e FITC 556910
CD86 BD 2331 (FUN-1) PE 555658
CD40 BD 5C3 FITC 555588
CD4 BD Leu-3a BV510 562970
CD4 BioLegend Leu-3 APC 357422
CD3 BD SK7 APC-Cy7 557832
CD25 BD M-A251 APC 555434
FoxP3 BD 259D/C7 Alexa 488 560047
CD39 BD TU66 APC 560239
CTLA-4 BD BNI3 PE 555853
PD-1 BD EH12.1 PE-Cy7 561272
Ki-67 BioLegend Ki-67 Alexa 488 350508
IFN-γ BioLegend 4SB3 FITC 502506
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin-Cy7 (PE-Cy7), 
allophycocyanin (APC), allophycocyanin-Cy7 (APC-Cy7), Brilliant Violet 421 (BV421), or 
Brilliant Violet 510 (BV510) conjugated mAbs anti-CD1a, CD14, CD16, CD80, CD86, 
HLA-DR, CD83, CD206, CD1c, CD11b, DC-SIGN, CD4, CD3, CD39, CTLA-4, PD-1, 
Ki-67, IFN-γ, FoxP3, and CD25 were obtained from BD Pharmingen or BioLegend.
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Preparation of Dcs, Macrophages,  
and cD4+ T cells
Buffy coats were obtained from healthy blood donors. Peripheral 
blood mononuclear cells (PBMCs) were isolated by standard den-
sity gradient centrifugation on Ficoll-Hypaque. Monocytes were 
obtained using CD14 microbeads (Miltenyi Biotec). The purity 
was checked by flow cytometry analysis using an anti-CD14 mAb 
and was found to be >95%. To obtain DCs, purified monocytes 
were cultured for 5  days in RPMI-1640 (Thermo Fisher) sup-
plemented with 10% heat-inactivated fetal calf serum, 50 U/ml 
penicillin, 50  µg/ml streptomycin, and 0.1  mM nonessential 
amino acids (complete culture medium; all from Thermo Fisher) 
at 1 × 106 cells/ml with 10 ng/ml IL-4 and 10 ng/ml GM-CSF, 
as previously described (39). These cells were labeled as control 
DCs. For DCs obtained in the presence of TGF-β and/or PGE2, 
concentrations are indicated in the text. In the figure legends, 
n indicates the number of individual donors of DCs.
For experiments involving treatment with EP2 and EP4 recep-
tor antagonists, monocytes were washed after 24  h of culture, 
then replated with IL-4 and GM-CSF for the remaining 4 days. 
To induce maturation, DCs were washed at day 5 of culture and 
treated with LPS (20 ng/ml).
Macrophages were prepared by plating CD14+ monocytes 
(purified as described below) with M-CSF (50 ng/ml) for 7 days. 
CD4+ T  cells were purified from monocyte-depleted PBMCs 
using microbeads for CD4 enrichment cocktail (Miltenyi Biotec).
T-cell-Dc co-cultures
Dendritic Cells Were Differentiated for 5 Days as 
Described Below
Maturation of DCs was induced by treatment with LPS (20 ng/ml) 
for 24 h. In all cases, DCs were washed, counted, and replated 
for incubation with freshly isolated allogeneic CD4+ T  cells 
(160,000 cells/well) in U-bottomed 96-well plates (Costar). Thus, 
co-cultures were always free of exogenous IL-4, GM-CSF, PGE2, 
or TGF-β.
Cell Proliferation Assays by CFSE Staining Dilution
Freshly isolated lymphocytes were labeled with 5,6-carboxy-
fluorescein succinimidyl ester (CFSE) (Invitrogen) at 1  µM 
concentration, according to the manufacturer’s instructions. 
CFSE-stained lymphocytes were coincubated with DCs using a 
DC:lymphocyte ratio of 1:4. After for 4 days, CD4+ T cells were 
stained with anti-CD3 mAb. Cellular proliferation was assayed 
by flow cytometry of CFSE staining in the CD3+ cell population.
Cell proliferation assays by Ki-67 intracytoplasmic staining. 
CD4+ T cells were coincubated with DCs for 2 days, stained with 
an anti-CD3 mAb and fixed. Intracytoplamic staining with anti-
Ki-67 mAb was performed using Perm/Wash kit (BD) according 
to the manufacturer’s instructions.
Flow cytometry
Fluorescein isothiocyanate, phycoerythrin, allophycocyanin, or 
Brilliant Violet 421 conjugated mAbs anti-CD1a, CD14, CD16, 
CD80, CD86, HLA-DR, CD83, CD206, CD1c, CD11b, DC-SIGN, 
CD4, CD3, CD39, CTLA-4, PD-1, Ki-67, IFN-γ, FoxP3, and 
CD25 were obtained from BD Pharmingen or BioLegend 
(Table 1). In all cases, isotype-matched control antibodies were 
used. Isotype staining and fluorescence minus one controls were 
performed using control DCs, DCs differentiated with PGE2 and 
with TGF-β (Figure S1 in Supplementary Material).
Analysis was performed by using a FACS Canto II flow 
cytometer (BD) and FlowJo X v10.0.7r2 software. The results 
are expressed as the mean fluorescence intensity (MFI), median 
fluorescence intensity, or as the percentage of positive cells.
Fluorescence Microscopy
CD1a Staining
Dendritic cells were placed on poly-l-lysine-coated glass cover-
slips (12 mm) for 30 min at room temperature. Then, cells were 
washed, fixed in 4% paraformaldehyde (10  min on ice), and 
washed twice with 0.1 mM glycine in PBS. Next, cells were incu-
bated with a mouse anti-CD1a mAb for 1 h, and then with Alexa 
594-conjugated anti-mouse mAb (Jackson ImmunoResearch 
Laboratories) for 1 h.
Smad2/3 Staining
Monocytes were placed on poly-l-lysine-coated glass coverslips 
(12  mm) for 20  min at room temperature. Then, cells were 
washed, fixed in 4% paraformaldehyde (10 min on ice), and 
washed twice with 0.1  mM glycine in PBS. Subsequently, cells 
were incubated with a mouse mAb anti-human Smad2/3 (BD 
catalog 610843, recognizes total Smad2 and Smad3 regardless of 
phosphorylation) for 1  h, and then with Alexa 488-conjugated 
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anti-mouse mAb (Jackson ImmunoResearch Laboratories) for 
45 min.
In both cases, coverslips were mounted on glass slides using 
DAPI-Fluoromount G. Immunofluorescence images were acquired 
with an Eclipse Ti-S fluorescence microscope (Nikon) using 
an S Fluor Plan 40× objective and images were analyzed using 
the NIS-Elements Imaging software version 4.20 (Nikon).
Quantitative real-Time rT-Pcr (Q-Pcr)
Total RNA was obtained from 1 ×  106 cells using RNEasy kit 
(QIAGEN) and then treated with DNAse for 15 min (SIGMA). 
Reverse transcription was carried out using M-MLV reverse 
transcriptase (SIGMA) according to the manufacturer’s instruc-
tions. Briefly, 500 ng of RNA was incubated for 50 min at 37°C 
in the presence of 150 ng of random hexamer primers (Thermo 
Fisher), 0.01 M DTT, and 10 mM dNTP mix. Q-PCR was per-
formed using Taqman Fast Master Mix (Thermo Fisher) in 10 µl 
reaction and Taqman gene expression kits, as follows: COX2 
(Hs00153133_m1) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (Hs99999905_m1). Reactions were carried out 
in a Step One Plus cycler (Thermo Fisher). The cycling program 
used was 95°C for 5 min followed by 40 cycles of 95°C for 5  s 
and 60°C for 30 s. Results are shown as 2−ΔCt using GAPDH as a 
reference gene (40).
Measurement of cytokine Production
Supernatant harvested from DC cultures or mixed lymphocyte 
cultures were diluted with culture medium and the presence 
of IL-10, IL-12p70, IL-6, IL-23, IFN-γ, and IL-5 was assessed 
by ELISA (BD Biosciences), according to the manufacturer’s 
recommendations. For determination of intracytoplasmic IFN-γ 
expression, CD4+ T cells were coincubated with DCs for 4 days 
and then stained with anti-CD4 mAb and fixed. Intracytoplamic 
staining with anti-IFN-γ mAb was performed using Perm/Wash 
kit (BD) according to the manufacturer’s instructions.
Western blot
Nuclear and cytosolic protein fractions were prepared using 
NE-PER kit (Thermo Fisher) according to the manufacturer’s 
instructions. Briefly, cells were washed in PBS, then the plasma 
membrane was lysed and nuclei were separated from cytosolic 
protein fraction by centrifugation for 10 min at 12,000 g. Nuclear 
protein extract was obtained by lysis in NER buffer. Protein 
extracts were quantified by BCA assay and resuspended in 
50 mM Tris–HCl pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, 
10% glycerol, and 0.05% bromophenol blue. Protein extracts 
(20 µg) were electrophoresed on 8–15% SDS polyacrylamide gel 
and transferred to PVDF membranes. Blots were blocked with 5% 
non-fat powdered milk in TBS containing 0.05% Tween-20 and 
probed with the indicated primary antibodies followed by horse-
radish-peroxidase-conjugated secondary antibodies. Reactivity 
was developed by enhanced chemiluminescence according to the 
manufacturer’s instructions (Kalium Technologies).
Primary antibodies were mouse anti-human Smad2/3 (BD), 
mouse anti-human histone deacetylase-1 (Abcam catalog 68436), 
and rabbit anti-human GAPDH (Abcam catalog 22555). To 
augment sensitivity of Smad2/3 western blot, a goat anti-mouse 
secondary antibody was used followed by an anti-goat antibody 
conjugated to horseradish peroxidase.
statistics
Statistical significance was calculated using GraphPad software. 
Student’s paired t-test was used to determine the significance of 
differences between two treatment groups. For multiple analyses, 
one-way or two-way ANOVA were used followed by Bonferroni’s 
posttest for selected multiple comparisons. When tests for paired 
samples were used, it has been indicated in the figure legend. 
p-Values <0.05 were considered statistically significant, indicated 
by symbol “*”. Symbol “#” has been used to indicate p values 
<0.05 when comparing control DCs versus TGF-β-treated DCs.
resUlTs
In a first set of experiments, we analyzed the combined effect of 
PGE2 and TGF-β on the phenotype of DCs. Human monocytes 
were cultured with IL-4 and GM-CSF for 5 days in the presence of 
TGF-β, PGE2, or both. Analysis at day 5 showed that control DCs 
expressed high levels of CD1a and were negative for the expres-
sion of CD14 (Figure 1A). In agreement with previous reports, 
addition of TGF-β in the course of DC differentiation further 
increased CD1a expression (17), while cells incubated with 
PGE2 did not gain expression of CD1a and maintained CD14 
expression (37, 41) (Figures 1A–C; Figure S2 in Supplementary 
Material). Analysis of DCs differentiated in the presence of both 
TGF-β and PGE2 revealed that PGE2 strongly antagonized the 
effects mediated by TGF-β in a concentration-dependent mode 
(Figures  1A–C). Remarkably, using concentrations of TGF-β 
similar to those found at inflammatory sites such as pleural effu-
sions, synovial fluid, and tumor-derived ascites (~0.25  ng/ml) 
(42–46), we found that all concentrations of PGE2 assessed 
markedly suppressed the expression of CD1a, preserving CD14 
expression (Figure 1D).
Additional experiments were then performed by analyz-
ing CD1a− CD14+ DCs (subpopulation gated as shown in 
Figure  2A) to define whether the phenotype obtained by dif-
ferentiating DCs in the presence of PGE2 plus TGF-β was similar 
to the phenotype of those DCs differentiated in the presence 
of PGE2 alone. The following markers were analyzed: CD11b, 
CD1c, CD80, CD86, CD40, CD16, CD206, and HLA-DR. All 
these experiments were performed using TGF-β concentrations 
of 0.25 and 2.5 ng/ml and PGE2 concentration of 10−7 M. No 
differences in cell viability were observed between control and 
PGE2 plus TGF-β-treated cells (Figure S3 in Supplementary 
Material). Our results indicated that DCs differentiated in the 
presence of PGE2 plus TGF-β and those differentiated in the 
presence of PGE2 alone showed a similar phenotype signature. 
However, TGF-β concentrations of 2.5  ng/ml significantly 
reduced the expression of CD86 and CD206 (Figure  2B). 
For comparison, phenotypic analysis of CD1a+ CD14− DCs 
obtained in control and TGF-β-treated cultures is shown in 
Figure S4 in Supplementary Material.
We then analyzed the ability of DCs to acquire a mature 
phenotype upon stimulation with LPS. As expected, control 
DCs increased the expression of HLA-DR, CD86, and CD83 in 
FigUre 1 | Presence of PGE2 during differentiation of DCs reverses the phenotype induced by TGF-β. Monocytes were incubated for 5 days with IL-4 and 
GM-CSF (control DCs), in the presence of TGF-β, PGE2, or a combination of both. Concentrations are as indicated. At day 5, expression of CD1a and CD14 was 
analyzed by flow cytometry. (a) Representative dot plots are shown. (b) Results from individual donors are expressed as MedFI with median bar. (c) Fluorescence 
microscopy of DCs stained with anti-CD1a and DAPI nuclear-staining. (D) Expression of CD1a and CD14 for different concentrations of PGE2 and TGF-β, as 
indicated. Bars indicate mean ± SEM of MedFI (n = 6). In all cases, * indicates p < 0.05 against control (i.e., condition without PGE2) as calculated after repeated-
measures two-way ANOVA test, followed by Bonferroni posttest for selected comparisons. Abbreviations: MedFI, median fluorescence intensity; MFI, mean 
fluorescence intensity; PGE2, prostaglandin E2; DCs, dendritic cells.
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FigUre 2 | Presence of PGE2 during differentiation of DCs imposes a phenotypic signature, regardless of addition of TGF-β. Monocytes were incubated for  
5 days with IL-4 and GM-CSF (control DCs), in the presence of TGF-β (0.25 and 2.5 ng/ml), PGE2 (10−7 M), or a combination of both. (a) Representative dot  
plots for expression of CD1a and CD14, showing gating of the CD1a− CD14+ subpopulation for further phenotypic analysis. (b). Representative dot plots and 
quantification showing expression of selected markers, analyzed in the CD1a−CD14+ subpopulation. Results from individual donors are expressed as MFI  
with median bar (n = 3–6). * indicates p < 0.05 as calculated after one-way ANOVA test, followed by Bonferroni posttest for selected comparisons.  
Abbreviations: MFI, mean fluorescence intensity; PGE2, prostaglandin E2; DCs, dendritic cells.
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FigUre 3 | Presence of PGE2 during differentiation of DCs determines a phenotype signature upon LPS stimulation, regardless of addition of TGF-β. Monocytes 
were incubated for 5 days with IL-4 and GM-CSF in the presence of PGE2 (10−7 M), with or without addition of TGF-β (0.25 and 2.5 ng/ml). Next, DCs were  
washed and exposed for 24 h to LPS (20 ng/ml). Further analysis was performed in the gated CD1a− CD14+ subpopulation. (a) Representative dot plots for 
expression of CD86 and HLA-DR, analyzed in the CD1a− CD14+ subpopulation. (b) Results from individual donors are expressed as MFI with median bar (n = 3). 
(c) Representative histograms for expression of CD83, analyzed in the CD1a− CD14+ subpopulation. (D) Results from individual donors are expressed as MFI  
with median bar (n = 4). In all cases, * indicates p < 0.05 as calculated after repeated-measures one-way ANOVA test. Abbreviations: MFI, mean fluorescence 
intensity; PGE2, prostaglandin E2; DCs, dendritic cells.
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FigUre 4 | Presence of PGE2 during differentiation of DCs prevents TGF-β-mediated inhibition of IL-10 and COX2 expression. (a) Monocytes were incubated  
for 5 days with IL-4 and GM-CSF (control DCs), in the presence or absence of TGF-β (0.25 and 2.5 ng/ml), PGE2 (10−7 M), or a combination of both. Next, DCs 
were washed and exposed for 24 h to LPS (20 ng/ml). IL-10, IL-6, IL-12p70, and IL-23 were measured by ELISA in culture supernatants (mean ± SEM, n = 4–7). 
(b) Monocytes were incubated for 5 days with IL-4 and GM-CSF (control DCs), in the presence of TGF-β (0.25 ng/ml), PGE2 (10−7 M), or a combination of both. 
Next, DCs were washed and exposed for 12 h to LPS (20 ng/ml). COX2 was measured by q-PCR (mean ± SEM, n = 3–5). In all cases, * indicates p < 0.05 as 
calculated after one-way ANOVA test. # indicates p < 0.05 comparing TGF-β-treated versus control DCs. Abbreviations: AU, arbitrary units; PGE2, prostaglandin  
E2; DCs, dendritic cells.
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response to LPS stimulation. DCs differentiated in the presence 
of PGE2 alone increased the expression of CD86 upon LPS 
stimulation, but not the expression of HLA-DR (Figures 3A,B). 
Expression of maturation marker CD83 was not be upregulated by 
LPS in these cells (Figures 3C,D). Interestingly, CD1a− CD14+ 
DCs differentiated in the presence of both PGE2 and TGF-β 
showed a similar response to LPS compared with those DCs 
differentiated in the presence of PGE2 alone (Figures  3A–D). 
In sharp contrast, DCs differentiated in the presence of TGF-β 
alone showed impaired expression of HLA-DR and CD86, 
but significantly increased the expression of CD83, upon LPS 
stimulation (Figure S5 in Supplementary Material), in agreement 
with previous reports (17, 18, 47). Taken together, these results 
suggest that PGE2 efficiently antagonizes the actions induced by 
TGF-β in terms of the LPS-induced phenotype of DCs.
Further studies were performed by studying the production 
of cytokines by LPS-stimulated DCs. Differentiation of DCs in 
the presence of PGE2 almost completely suppressed DC ability 
to produce IL-12 and IL-23, while increased the production of 
IL-10 without modifying the production of IL-6 compared with 
control DCs (Figure 4A). Conversely, differentiation of DCs in 
the presence of TGF-β substantially suppressed the production 
of IL-10 and IL-6. DCs differentiated in the presence of both 
TGF-β and PGE2 showed a pattern of cytokine production 
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similar to DCs differentiated in the presence of PGE2 alone, 
although this effect was less marked when TGF-β was used at 
2.5  ng/ml (Figure  4A), suggesting that antagonism of TGF-β 
by PGE2 is less efficient at a higher TGF-β concentration (in 
agreement with data from CD1a and CD14 expression as 
shown in Figure  1). Furthermore, we studied the expression 
of prostaglandin-endoperoxide synthase-2 [cyclooxygenase-2 
(COX2)], since PGE2 has been reported to redirect DCs toward 
a tolerogenic phenotype by inducing COX2 expression and 
triggering a positive feedback loop (25, 43). We confirmed that 
PGE2 increased COX2 expression compared to control DCs 
(Figure  4B). We also found that TGF-β-treated DCs reduced 
LPS-induced expression of COX2 compared to control, whereas 
the addition of PGE2 reversed this inhibition, again supporting 
the conclusion that PGE2 antagonizes the effect of TGF-β.
We then analyzed the ability of LPS-stimulated DCs differenti-
ated with TGF-β, PGE2, or both, to induce T cell proliferation by 
co-culturing DCs with allogeneic lymphocytes. Cell proliferation 
was analyzed by measuring either Ki-67 intracellular staining or 
CFSE dilution. All the different DC populations showed a high 
allostimulatory activity and no differences were observed among 
them (Figures 5A,B). This observation suggests that monocytes 
differentiated with GM-CSF plus IL-4, in the presence of PGE2 
or PGE2 plus TGF-β, actually function as DCs in terms of their 
allostimulatory activity. This contrasts with the observations 
made with macrophages obtained from monocytes treated 
with M-CSF, which showed a very poor ability to stimulate the 
proliferation of allogeneic lymphocytes (Figure 5C). In spite of 
their similar allostimulatory activity, the different DC popula-
tions stimulated the production of cytokines by lymphocytes in a 
distinct fashion. Control DCs as well as DCs differentiated in the 
presence of TGF-β strongly stimulated the production of IFN-γ by 
allogeneic lymphocytes. A significant lower production of IFN-γ, 
however, was observed using DCs differentiated in the presence 
of PGE2 or PGE2 plus TGF-β (Figures 6A,B). By contrast, IL-5 
production was undetectable in cultures prepared with control 
DCs and DCs differentiated in the presence of TGF-β, while an 
increased production of IL-5 was observed in cultures performed 
with DCs differentiated in the presence of PGE2 or PGE2 plus 
TGF-β (Figure 6C). On the other hand, analysis of the frequency 
of CD4+ CD25+ FOXP3+ T cells in the course of the mixture 
lymphocyte reaction revealed that cultures prepared with DCs 
differentiated in the presence of PGE2 or PGE2 plus TGF-β 
showed a higher frequency of this cell population (Figure  7A; 
Figure S6 in Supplementary Material). Supporting that CD4+ 
CD25+ FOXP3+ T cells are actually regulatory T cells, we found 
that these cells expressed higher levels of the T regulatory cell-
makers CD39, PD-1, and intracellular CTLA-4 compared with 
CD4+ CD25+ FOXP3− T cells (Figure 7B). We conclude from 
these results that DCs differentiated in the presence of PGE2 and 
TGF-β, like DCs differentiated in the presence of PGE2 alone, 
prevent the activation of CD4+ T  cells in a pro-inflammatory 
profile, promoting a regulatory signature.
We performed additional experiments to analyze the mecha-
nisms through which PGE2 antagonized the actions induced 
by TGF-β in the course of DC differentiation. Analysis of DC 
phenotype performed at 5  days of culture revealed that the 
ability of TGF-β to increase CD1a expression was only modestly 
inhibited when PGE2 was added 3 h after the addition of TGF-β, 
while addition of PGE2 24 h later had no effect at all (Figure 8A). 
In agreement with this finding, removing PGE2 at either 3 or 
24  h after the culture start did not impair the acquisition of a 
CD1a− CD14+ phenotype by DCs (Figure  8B). Consistent 
with these observations, we found that the ability of PGE2 to 
stimulate COX2 expression and IL-10 production was induced at 
early time points, even in the presence of TGF-β (Figures 8C,D). 
Taking these observations into account, we decided to analyze 
the changes in the expression of CD14 and CD16 by monocytes 
at 24 h of culture. At this time point, monocytes cultured with 
GM-CSF plus IL-4 did not express CD1a (data not shown), and 
showed an increased frequency of CD14hi CD16int cells [defined 
as intermediate monocytes (48)], compared with freshly isolated 
monocytes. The acquisition of this phenotype signature was 
further increased by TGF-β and was strongly prevented by PGE2 
(Figures 9A–D). Together, these observations suggest that PGE2 
antagonizes the effects induced by TGF-β on DC differentiation 
acting at early time points.
Finally, we looked for possible mechanisms explaining the 
interaction of PGE2 and TGF-β signaling pathways. Monocytes 
express only two out of four E-prostanoid receptors, namely EP2 
and EP4 (49, 50). We used EP2 receptor antagonist PF-04418948 
(25 µM) and EP4 receptor antagonist L-161,982 (25 µM). Blocking 
EP2 or EP4 receptors separately only partially prevented the effect 
induced by PGE2. By contrast, it was completely prevented by 
incubating monocytes with both antagonists (Figures  10A,B). 
We speculated that a shared signaling cascade between the two 
EP receptors could be responsible for the inhibition of TGF-β 
actions. Since both EP2 and EP4 are coupled to an increase in 
intracellular cAMP, we hypothesized that this pathway could be 
responsible for antagonizing TGF-β signaling.
Previous studies in fibroblasts have demonstrated that a cAMP 
increase, followed by PKA-induced phosphorylation of cAMP-
responsive-element binding protein (CREB), leads to sequestra-
tion of transcriptional coactivator CBP/p300, also involved in 
Smad-mediated transcription, and consequently to weakening 
of TGF-β signaling (38). To evaluate this mechanism, we first 
tested whether forskolin, an adenylyl cyclase activator, mimicked 
the effect of PGE2. In fact, monocyte differentiation in the pres-
ence of forskolin (10 and 100  µM) resulted in CD1a− CD14+ 
DCs, regardless of the presence of TGF-β (Figure 10C) and thus 
confirmed that cAMP elevation counteracts TGF-β activity. 
Accordingly, the PKA inhibitor H-89 (10 µM) partially prevented 
the effect induced by PGE2, either in the absence or presence 
of TGF-β (Figure 10D), further supporting a role of the cAMP–
PKA pathway in the actions exerted by PGE2 (Figure 10D). By 
contrast, inhibition of EP4-activated PIK3γ by treatment with 
AS-605240 (10 µM) did not prevent PGE2 actions (Figure 10E). 
On the other hand, results in Figure 11A shows that differentia-
tion of DCs in the presence of PGE2 did not result in the inhibi-
tion of TGF-β receptor type II expression. In addition, we studied 
the cellular localization of Smad2 and Smad3 after treatment 
of monocytes with TGF-β, PGE2, or both. Smad2 and Smad3 
are two transcription factors that localize to the nucleus when 
phosphorylated as part of the canonical TGF-β-signaling cascade 
FigUre 5 | Dendritic cells (DCs) differentiated in the presence of prostaglandin E2 (PGE2), TGF-β, or a combination of both are all equally capable of inducing 
proliferation of allogeneic lymphocytes. Monocytes were incubated for 5 days with IL-4 and GM-CSF (control DCs), in the presence of TGF-β (0.25 and 2.5 ng/ml), 
PGE2 (10−7 M), or a combination of both. Next, DCs were washed and exposed for 24 h to LPS (20 ng/ml). (a) LPS-stimulated DCs were washed and incubated 
with allogeneic CD4+ T cells using a DC:lymphocyte ratio of 1:4. At day 3, cells were harvested and the expression of Ki-67 was analyzed by intracellular staining 
and flow cytometry in the gate of CD3+ T cells. Representative dot plots are shown. Results from individual donors are expressed as % of Ki-67+ cells with mean 
bar (n = 3–4). (b) LPS-stimulated DCs were washed and incubated with CFSE-labeled allogeneic CD4+ T cells, using a DC:lymphocyte ratio of 1:4. At day 4, the 
dilution of CFSE staining in the gate of CD3+ T cells was measured by flow cytometry. Lymphocytes cultured alone with or without PHA (10 µg/ml) were used  
as positive and negative controls, respectively. Representative dot plots are shown. Results from individual donors are expressed as % of CFSE-low cells with  
mean bar (n = 3–6). (c) Monocytes were incubated for 7 days with M-CSF. Next, macrophages were washed and exposed, or not, for 24 h to LPS (50 ng/ml). 
Macrophages were washed and incubated with allogeneic CD4+ T cells using a macrophage:lymphocyte ratio of 1:4. The proliferative response of T cells  
was analyzed at day 4 by measuring the dilution of CFSE staining in the gate of CD3+ T cells by flow cytometry. Representative dot plots are shown (n = 3).
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(9). We analyzed total Smad2/3 cellular localization by western 
blot and fluorescence microscopy and confirmed that PGE2 did 
not interfere with TGF-β-induced translocation of Smad2/3 into 
the nucleus (Figures 11B,C). Altogether, our results indicate that 
PGE2 interference of TGF-β signaling is mediated through eleva-
tion of cAMP and PKA activity, without compromising Smad2/3 
FigUre 6 | Prostaglandin E2 (PGE2) redirects differentiation of dendritic cells (DCs) suppressing IFN-γ production in mixed lymphocyte cultures, regardless of 
TGF-β addition. Monocytes were incubated for 5 days with IL-4 and GM-CSF (control DCs), in the presence of TGF-β (0.25 and 2.5 ng/ml), PGE2 (10−7 M), or a 
combination of both. Next, DCs were washed and exposed for 24 h to LPS (20 ng/ml). (a) LPS-stimulated DCs were washed and incubated with allogeneic CD4+ 
T cells using a DC:lymphocyte ratio of 1:4. At day 4, cells were harvested and the expression of IFN-γ was analyzed by intracellular staining and flow cytometry  
in the gate of CD4+ T cells. Representative dot plots are shown. Results from individual donors are expressed as % of IFN-γ+ cells with mean bar (n = 4–6). * 
indicates p < 0.05 as calculated after repeated-measures one-way ANOVA test, followed by Bonferroni posttest for selected comparisons. (b) IFN-γ and  
(c) IL-5 were measured by ELISA in culture supernatants at day 4 (mean ± SEM, n = 4–7). * indicates p < 0.05 as calculated after one-way ANOVA test.
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activation by TGF-β. Interestingly, a similar mechanism through 
which PGE2 antagonizes the effect of TGF-β has been previously 
described in fibroblasts (38).
DiscUssiOn
Dendritic cells are a heterogeneous group of cells that share 
strong antigen-presenting capabilities, but differ in their ontog-
eny, phenotype, and other functional characteristics. In the steady 
state, DCs resident in lymphoid organs as well as migratory 
DCs populating peripheral tissues originate from circulating 
committed precursors. Thus, in non-inflammatory conditions, 
most populations of DCs are replenished from these precur-
sors without requirement of monocyte input from blood (51). 
By contrast, during pathogen-induced or sterile inflammation, 
blood monocytes infiltrate the inflammation site and give raise to 
a distinct subset of DCs termed inflammatory DCs.
In mouse, the relevance of monocyte-derived inflammatory 
DCs has been established for several years (52). For instance, they 
have been proven necessary for protective Th1 responses against 
Leishmania major, HSV-2, or influenza virus (2, 52, 53), as well as 
Th2 responses (4, 54) and even for the prevention of exacerbated 
local innate responses after Toxoplasma gondii infection (6). 
In humans, characterization of inflammatory DCs has lagged 
behind, but still they have been described in synovial fluid from 
rheumatoid arthritis patients, tumor-derived ascites and skin 
from psoriasis and atopic dermatitis patients (1, 55, 56), where 
they have also been linked to different profiles of the immune 
response.
From these studies, it becomes clear that infiltrating mono-
cytes are highly plastic cells. In this regard, a comprehensive 
transcriptional profiling study demonstrated that the functional 
properties of tissue-resident DCs (from skin and lungs) are 
defined mainly by their ontogeny, whereas the profile acquired 
by monocyte-derived inflammatory DCs is rather dependent 
on microenvironmental signals (7). In the same sense, two 
recent studies using single-cell RNA-seq transcriptomics have 
shown homogeneous gene expression signatures within the 
blood CD14+ monocytes subset (57, 58), thus indicating that 
monocytes are not predetermined but instead rely on external 
signals to define their fate. For instance, Goudot et al. observed 
that a uniform population of CD14+ monocytes could switch 
FigUre 7 | PGE2 redirects differentiation of DCs promoting the expansion of CD25+ FoxP3+ T cells, regardless of TGF-β addition. Monocytes were 
incubated for 5 days with IL-4 and GM-CSF (control DCs), in the presence of TGF-β (0.25 and 2.5 ng/ml), PGE2 (10−7 M), or a combination of both. Next,  
DCs were washed and exposed for 24 h to LPS (20 ng/ml). LPS-stimulated DCs were washed and incubated with allogeneic CD4+ T cells using a 
DC:lymphocyte ratio of 1:4 for 4 days. (a) Representative dot plots for expression of CD25 and FoxP3, analyzed in the CD4+ subpopulation. Results from 
individual donors are expressed as % of double positive CD25+ FoxP3+ cells with mean bar (n = 3–8). * indicates p < 0.05 as calculated after one-way 
ANOVA test, followed by Bonferroni posttest for selected comparisons. (b) Representative histograms for expression of CD39, PD-1, and intracytoplasmic 
CTLA-4, analyzed in the CD25+ FoxP3− and the CD25+ FoxP3+ subpopulations (n = 3). Abbreviations: FMO, fluorescence minus one controls; PGE2, 
prostaglandin E2; DCs, dendritic cells.
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their transcriptional program to differentiate either to DCs or 
macrophages (58). Interestingly, the proportion of one cell type 
over the other correlated dose-dependently with the presence 
of ligands to the aryl hydrocarbon receptor, providing a hint to 
devise the environmental signals involved in the differentiation 
of inflammatory DCs. However, the factors affecting the dif-
ferentiation of monocytes to DCs in  vivo still remain largely 
unknown.
FigUre 8 | Prostaglandin E2 (PGE2) interferes with TGF-β actions acting at early time points after the onset of differentiation. (a) Monocytes were incubated  
with IL-4 and GM-CSF [control dendritic cells (DCs)], in the presence of TGF-β (0.25 ng/ml), PGE2 (10−7 M), or a combination of both. When indicated, PGE2  
was added 3 and 24 h after the addition of TGF-β. At day 5, expression of CD1a and CD14 was analyzed by flow cytometry. Representative dot plots are shown 
(n = 3). (b) Monocytes were incubated with IL-4 and GM-CSF (control DCs), in the absence or in the presence of PGE2 (10−7 M). Cells were washed after 3 or 24 h 
of culture, and cultured in medium with IL-4 and GM-CSF without PGE2. At day 5, expression of CD1a and CD14 was analyzed by flow cytometry. Representative 
dot plots are shown (n = 3). (c) Monocytes were incubated as in (a), but total RNA was extracted at 5 h of culture. COX2 was measured by q-PCR (mean ± SEM, 
n = 4). Abbreviation: AU, arbitrary units. (D) Monocytes were incubated as in (a), but IL-10 was measured at 24 h by ELISA in culture supernatants (mean ± SEM, 
n = 6). In all cases, * indicates p < 0.05 as calculated after one-way ANOVA test, followed by Bonferroni posttest for selected comparisons.
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TGF-β and PGE2 are two ubiquitous immunomodulators 
known to coexist in inflammatory sites and the tumor microen-
vironment (59, 60), where differentiation of DCs from monocytes 
takes place. Here, we focused on the interaction of these two 
mediators acting on monocytes during their differentiation to 
DCs, as opposed to studying their actions on fully differentiated 
DCs. A review of the literature revealed that key properties of 
DCs, most notably the cytokine expression pattern, are modu-
lated in opposite ways by the presence of TGF-β and PGE2 during 
differentiation (17, 21). In this work, we studied how these two 
factors affected the outcome of DC differentiation when acting 
together. Using the well-known model of DC differentiation 
induced by IL-4 and GM-CSF (61), we found that incubation with 
PGE2 promoted IL-10-producing DCs which induced expansion 
of CD25+ FoxP3+ T  cells, whereas incubation with TGF-β 
blocked IL-10 but enabled the differentiation of IL-12-producing 
DCs capable of stimulating Th1 responses. Remarkably, when 
we added PGE2 and TGF-β together at physiologically relevant 
concentrations, we found that PGE2 overcame the influence of 
TGF-β, leading to DCs that produced high levels of IL-10 but 
not IL-12, upregulated the expression of COX2, did not mature 
completely in response to LPS and promoted the expansion 
of regulatory T  lymphocytes. Previous studies demonstrated 
that PGE2 is linked to the in vitro and in vivo development of 
MDSCs (25, 62). In this context, our results further underscore 
the relevance of PGE2 as an immunosuppressive factor acting on 
the differentiation of DCs. What is more, our data showed that 
antagonizing TGF-β required the presence of PGE2 only at the 
beginning of the differentiation process, thus opening the pos-
sibility that short spikes of PGE2 levels could instruct monocytes 
to disregard longer TGF-β signals. Interestingly, this temporal 
succession has actually been described in a murine model of acute 
peritonitis followed by a resolution period (63). In summary, we 
conclude that the presence of PGE2 is likely to minimize the 
effects mediated by TGF-β on the differentiation of DCs.
These results are consistent with our previous report inves-
tigating the differentiation of DCs in the presence of seminal 
plasma, a fluid extremely rich in TGF-β and prostanoids of the E 
series, including PGE1, PGE2, and their 19-OH-derivatives (37). 
Deposition of semen triggers an inflammatory reaction involving 
secretion of CCL2, IL-8, and GM-CSF by epithelial cells, which 
leads to a rapid influx of CD14+ monocytes to the genital mucosa 
(64). In this context, inflammatory monocytes may be exposed to 
seminal TGF-β1, averaging 200 ng/ml, as well as PGE prostanoids 
which can reach values in semen as high as 10−3M (35, 36, 65). By 
incubating monocytes in the presence of seminal plasma, together 
FigUre 9 | Presence of PGE2 antagonizes the induction of CD16 expression mediated by TGF-β. (a–D) Monocytes were obtained using CD14 microbeads and 
then incubated with IL-4 and GM-CSF (control) or with addition of TGF-β (concentrations as indicated), PGE2 (10−7 M), or a combination of both. At 24 h, expression 
of CD14 and CD16 was analyzed by flow cytometry and classical, intermediate, and non-classical monocyte subsets were defined as shown. (a) Representative 
dot plots are shown. (b) Quantification of intermediate monocyte subset (mean ± SEM, n = 4). (c) Expression of CD14 in the whole monocyte population 
(mean ± SEM, n = 4). (D) Quantification of monocyte subsets (n = 7). Results from individual donors are expressed as % of cells with median bar, obtained from 
cultures using TGF-β at 0.25 and 2.5 ng/ml. In all cases, * indicates p < 0.05 as calculated after repeated-measures two-way ANOVA test, followed by Bonferroni 
posttest for selected comparisons. # indicates p < 0.05 comparing TGF-β versus control DCs. Abbreviations: MFI, mean fluorescence intensity; PGE2, prostaglandin 
E2; DCs, dendritic cells.
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with IL-4 and GM-CSF, we obtained CD1a− CD14+ DCs with 
enhanced production of IL-10 that promoted the expansion of 
FoxP3+ regulatory T cells (37). Notably, antagonizing receptors 
EP2 and EP4 abrogated the effect induced by seminal plasma and 
resulted in DCs bearing the typical CD1a+ CD14− phenotype. 
We concluded that seminal plasma prostaglandins were respon-
sible for the generation of tolerogenic DCs, thus providing a 
possible mechanism for previous observations indicating that 
exposure to semen, even in the absence of embryo implantation, 
was associated with the expansion of regulatory T cells specific 
to paternal antigens (66, 67). Therefore, our previous results 
together with the present work indicate that TGF-β does not play 
a critical role in promoting a tolerogenic profile in DCs that sur-
vey paternal antigens. On the other hand, Sharkey et al. elegantly 
demonstrated that seminal TGF-β induced the secretion of IL-6, 
CCL2, and GM-CSF from epithelial cells, indicating that TGF-β 
contributed importantly to the initial inflammatory response in 
the genital mucosa (68).
The effect of TGF-β on myeloid cell differentiation has been 
associated with the development of LCs, since TGF-β is required 
FigUre 10 | Prostaglandin E2 (PGE2) interferes with TGF-β actions by stimulating the increase in intracellular cyclic adenosine mono-phosphate increase and 
protein kinase A (PKA) activity. (a,b) Monocytes were pre-incubated for 20 min with EP2 receptor antagonist PF-04418948 (25 µM), EP4 receptor antagonist 
L-161,982 (25 µM), or both. Then, cells were cultured with IL-4 and GM-CSF, in the absence or presence of TGF-β (0.25 ng/ml), PGE2 (10−7 M), or a combination  
of both. At 24 h, cells were washed and cultured in medium with IL-4 and GM-CSF without PGE2 or TGF-β. At day 5, expression of CD1a and CD14 was analyzed 
by flow cytometry (mean ± SEM, n = 4–6). Representative dot plots are shown in (a). (c) Monocytes were incubated with IL-4 and GM-CSF, in the absence or 
presence of TGF-β (0.25 ng/ml), the adenylate cyclase activator forskolin (10 and 100 µM), or a combination of both. At day 5, expression of CD1a and CD14 was 
analyzed by flow cytometry (mean ± SEM, n = 3). (D,e) Monocytes were pre-incubated for 1 h with (D) PKA inhibitor H89 (10 µM) or (e) phosphatidylinositol-3-
phosphate kinase (PI3K) inhibitor AS-605240 (10 µM) before differentiation with IL-4 and GM-CSF, performed in the absence or presence of TGF-β (0.25 ng/ml), 
PGE2 (10−7 M), or a combination of both. At 24 h, cells were washed and incubated without antagonists. At day 5, expression of CD1a and CD14 was analyzed  
by flow cytometry (mean ± SEM, n = 4–5). In all cases, * indicates p < 0.05 as calculated after repeated-measures two-way ANOVA test, followed by Bonferroni 
posttest for selected comparisons. # indicates p < 0.05 comparing TGF-β-treated dendritic cells (DCs) versus control DCs.
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FigUre 11 | Prostaglandin E2 (PGE2) interferes neither with TGF-β receptor type II expression nor with TGF-β-induced Smad2/3 entry into the nucleus.  
(a) Monocytes were incubated with IL-4 and GM-CSF (control), in the absence or presence of TGF-β (0.25 and 2.5 ng/ml), PGE2 (10−7 M), or a combination of  
both. At 3 h, expression of TGF-β receptor type II was analyzed by flow cytometry (representative histograms shown, n = 3). Also shown are isotype staining control 
and staining only with secondary antibody (Alexa-594-conjugated anti-mouse). (b,c) Monocytes were incubated for 45 min with IL-4 and GM-CSF, in the absence 
or presence of TGF-β (1 ng/ml), PGE2 (10−7 M), or a combination of both. In (b), cytoplasmic and nuclear extracts were prepared and total Smad2/3 was analyzed 
by western blot. Histone deacetylase-1 (HDAC1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as nuclear and cytoplasmic markers, 
respectively. Representative blots from n = 3 are shown. N, nuclear extract; C, cytoplasmic extract. In (c), cells were fixed at 45 min and stained with  
anti-Smad2/3 for fluorescence microscopy. Representative photographs from n = 3 are shown.
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for the development of LCs in vivo and in vitro from CD34+ as well 
as CD1c+ blood precursors (69–71). In inflammatory conditions, 
LCs could be derived from circulating monocytes (72), in a pro-
cess where TGF-β plays a critical role (73). Thus, our study could 
be understood as an investigation on the potential disruption 
elicited by PGE2 on the differentiation of LCs. A seminal paper by 
Geissmann et al. reported that addition of TGF-β to monocytes 
incubated with IL-4 and GM-CSF leads to a LC-like phenotype 
characterized by high expression of CD1a and E-cadherin (74). 
Consistent with our results, these cells were characterized by their 
inability to express IL-10 when stimulated by LPS, CD40-ligand, 
or a cytokine cocktail including TNF-α and IL-1β (17). As a 
matter of fact, their inability to produce IL-10 upon stimulation, 
while retaining their ability to produce IL-12, has been the most 
consistent characteristic observed in TGF-β-derived DCs (17, 18, 
75, 76). By contrast, their maturation phenotype and ability to 
induce T cell proliferation are less consistent and appear to vary 
depending on TGF-β concentration and the stimuli used for acti-
vation (17, 47, 76, 77). Most studies used concentrations higher 
than 2 ng/ml of TGF-β and found a reduced expression of CD80, 
CD86, and CD83, as well as an attenuated induction of T  cell 
proliferation (17, 47, 76). In our hands, monocytes differentiated 
in the presence of 0.25 ng/ml of TGF-β still retained the ability 
to upregulate coestimulatory molecules after LPS stimulation, 
whereas differentiation at 2.5  ng/ml abrogated this capacity, in 
agreement with a previous study that also observed concentration-
dependent effects of TGF-β on the phenotype of DCs (77). We 
also observed contrasting effects of high and low dose of TGF-β 
on IL-12 and IL-23 production, further emphasizing the point 
that TGF-β acts on monocytes in a concentration-dependent 
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mode. When analyzing DCs differentiated with PGE2, we also 
noted differences between treatment with lower and higher 
concentrations of TGF-β. The antagonizing effect of PGE2 was 
less marked against higher TGF-β levels (2.5 ng/ml) particularly 
on the proportion of CD1a− CD14+ cells, basal and LPS-induced 
expression of CD86, and the cytokine expression pattern. These 
results are consistent with a competition between PGE2 and 
TGF-β signaling pathways, in which higher levels of TGF-β are 
needed to counteract increasing levels of PGE2.
Nonetheless, the antagonism exerted by PGE2 might be 
physiologically relevant in view of the available data regarding 
TGF-β levels in vivo. The actual concentration of active TGF-β 
at inflammation or tumor sites is still debated, given that its 
activation is a regulated process and the extracellular matrix acts 
as a reservoir of latent TGF-β, enabling local spikes of TGF-β 
levels not reflected by measurements in plasma (78, 79). Total 
TGF-β levels in inflammatory fluids fluctuate, for instance, 
between 1.48  ng/ml in ascites from hepatocarcinoma cirrhotic 
patients, 2  ng/ml in ascites from ovarian cancer patients, and 
9.75 ng/ml in pleural effusion of pneumonia patients (42, 43, 45). 
However, activated TGF-β levels are substantially lower. 
In the hepatocarcinoma cirrhotic patients, active TGF-β1 in 
ascites averaged 0.001  ng/ml (42). In other study analyzing 
human synovial fluid, Albro et al. found an average of 2 ng/ml of 
total TGF-β but negligible amounts of the active form, which rose 
to 0.3 ng/ml after 2 h of mechanical activation (44).
When studied in non-immune experimental systems, PGE2 
and TGF-β commonly displayed antagonism, as illustrated by 
PGE2 inhibition of TGF-β-induced collagen synthesis in lung 
fibroblasts, epithelial–mesenchymal transition in breast cancer 
or TGF-β-induced differentiation of myofibroblasts (26–28, 80). 
However, PGE2 has shown synergistic effects with TGF-β on a 
number of cases, most notably the induction of FoxP3 expression 
in CD4+ T lymphocytes [(32, 33) and unpublished observations]. 
The difference between the synergy in FoxP3 expression and the 
antagonism described in this paper could be explained by a model 
put forward by Schiller et al. when they studied the interaction of 
cAMP with the TGF-β transduction pathway in fibroblasts (38). 
Canonical signaling by TGF-β induces Smad2/3 phosphoryla-
tion and entry into the nucleus, modulating downstream gene 
expression (9). On the other hand, PGE2 receptors EP2 and 
EP4 are coupled to activation of cAMP-induced PKA and also 
of PI3K, both of which are capable of phosphorylating CREB 
transcription factor (81). Schiller et al. proposed that, for some 
genes, cAMP-induced CREB competed with TGF-β-induced 
Smad3 for the same transcriptional coactivator (CBP/p300), 
whereas for other set of genes, in which Smad binding sites and 
CRE sites coexist, there is a synergistic effect. In agreement with 
this model, the FoxP3 locus presents Smad binding sites as well 
as CREB/ATF binding sites in the enhancer region located in 
intron 2 (82–84). When studying the antagonism in monocytes, 
in accordance with the competition model, we found TGF-β-
induced accumulation of Smad2/3 in the nucleus regardless of 
the presence of PGE2. In addition, we demonstrated that PGE2 
interference of TGF-β could be mimicked by cAMP-elevating 
agents and could be blocked by inhibition of PKA activity. Of 
note, we did observe a concentration-dependent effect when we 
used different amounts of forskolin to compete TGF-β signaling, 
something that Schiller et  al. (38) did not investigate. In this 
sense, a second study on fibroblast using physiological (lower) 
levels of cAMP was not able to antagonize TGF-β-induced gene 
expression (85), further emphasizing the idea that the outcome is 
concentration-dependent.
A mechanism based on competition that depends on a 
variable ratio of concentrations of PGE2 and TGF-β could 
explain, at least partially, the heterogeneity observed in inflam-
matory DCs. For instance, when characterizing inflammatory 
DCs from synovial fluid and tumor ascites, Segura et al. have 
shown the existence of two subpopulations represented by 
CD16+ CD1c− cells and CD16− CD1c+ cells (5). These sub-
populations overlap with our results where TGF-β promotes 
the CD16− CD1c+ phenotype while PGE2 promotes the other 
one. Notably, this phenotypic similarity extends to expression 
of markers HLA-DR, CD11b, and CD206 in both populations. 
In a different scenario, tumor DCs are also known as a hetero-
geneous population, where the presence of immunosuppressive 
tumor-promoting DCs associated with PGE2 is firmly estab-
lished, although it is also clear that they coexist with several 
highly immunogenic types (86, 87). Particularly, expression 
of CD1a has been used to classify tumor DCs, for example, in 
breast and colorectal cancer (88). Interestingly, it has also been 
shown that tumor-derived prostanoids inhibit CD1a expression 
in DCs, even in the presence of TGF-β, further emphasizing 
the idea that PGE2 plays a defining role in the phenotype of 
DCs (62, 89, 90).
In summary, our results strongly suggest that the role of 
TGF-β in the differentiation of DCs is curtailed by the presence 
of PGE2, which might be often the case in physiological and 
pathological conditions. While our work concentrated on DCs, 
it remains to be seen whether PGE2 also interferes TGF-β dur-
ing the differentiation of other monocyte-derived myeloid cells, 
such as inflammatory and some tissue-resident macrophages. 
All in all, the data presented in this article underscores the 
complexity of myeloid cell differentiation, a dynamic process 
in which changing concentrations of various factors add up to 
define the final outcome. In this context, the heterogeneity usu-
ally observed in cell populations from biological samples could 
be understood as a reflection of the history of factors sensed by 
each individual cell. Further work addressing this complexity 
is needed to eventually manipulate DCs for their use in cancer, 
autoimmune, and transplant therapies.
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